PCI Biotech (Norway) Probability of Future Stock Price Finishing Over 1.90

PCIB Stock  NOK 1.90  0.58  43.94%   
PCI Biotech's future price is the expected price of PCI Biotech instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of PCI Biotech Holding performance during a given time horizon utilizing its historical volatility. Check out PCI Biotech Backtesting, PCI Biotech Valuation, PCI Biotech Correlation, PCI Biotech Hype Analysis, PCI Biotech Volatility, PCI Biotech History as well as PCI Biotech Performance.
  
Please specify PCI Biotech's target price for which you would like PCI Biotech odds to be computed.

PCI Biotech Target Price Odds to finish over 1.90

The tendency of PCI Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.90 90 days 1.90 
about 11.3
Based on a normal probability distribution, the odds of PCI Biotech to move above the current price in 90 days from now is about 11.3 (This PCI Biotech Holding probability density function shows the probability of PCI Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon the stock has the beta coefficient of 1.76 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PCI Biotech will likely underperform. Additionally PCI Biotech Holding has an alpha of 0.1235, implying that it can generate a 0.12 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   PCI Biotech Price Density   
       Price  

Predictive Modules for PCI Biotech

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PCI Biotech Holding. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.101.908.61
Details
Intrinsic
Valuation
LowRealHigh
0.071.468.17
Details

PCI Biotech Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. PCI Biotech is not an exception. The market had few large corrections towards the PCI Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PCI Biotech Holding, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PCI Biotech within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.12
β
Beta against Dow Jones1.76
σ
Overall volatility
0.19
Ir
Information ratio 0.03

PCI Biotech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PCI Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PCI Biotech Holding can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
PCI Biotech Holding had very high historical volatility over the last 90 days
PCI Biotech Holding may become a speculative penny stock
The company reported the revenue of 6.27 M. Net Loss for the year was (88.39 M) with profit before overhead, payroll, taxes, and interest of 6.27 M.
PCI Biotech Holding has accumulated about 116.12 M in cash with (68.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 32.0% of the company outstanding shares are owned by corporate insiders

PCI Biotech Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PCI Stock often depends not only on the future outlook of the current and potential PCI Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PCI Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding107.5 M
Cash And Short Term Investments115.2 M

PCI Biotech Technical Analysis

PCI Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. PCI Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PCI Biotech Holding. In general, you should focus on analyzing PCI Stock price patterns and their correlations with different microeconomic environments and drivers.

PCI Biotech Predictive Forecast Models

PCI Biotech's time-series forecasting models is one of many PCI Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PCI Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about PCI Biotech Holding

Checking the ongoing alerts about PCI Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PCI Biotech Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
PCI Biotech Holding had very high historical volatility over the last 90 days
PCI Biotech Holding may become a speculative penny stock
The company reported the revenue of 6.27 M. Net Loss for the year was (88.39 M) with profit before overhead, payroll, taxes, and interest of 6.27 M.
PCI Biotech Holding has accumulated about 116.12 M in cash with (68.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 32.0% of the company outstanding shares are owned by corporate insiders

Other Information on Investing in PCI Stock

PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.